# Chang-Ik Yoon: Not applicable (device, behavioral) study in Breast Neoplasm Malignant Primary, Lymphedema Arm (264 participants)

**Score:** 65/100

| Field | Value |
|---|---|
| Sponsor | Chang-Ik Yoon |
| Sponsor type | Academic and hospital |
| Study | Agentic AI App and Home Bioimpedance Monitoring for Endocrine Therapy Adherence and Lymphedema in Breast Cancer Survivors |
| NCT ID | NCT07911839 |
| Phase | Not applicable (device, behavioral) |
| Status | not yet recruiting |
| Conditions | Breast Neoplasm Malignant Primary; Lymphedema Arm; Medication Adherence; Ductal Carcinoma In Situ |
| Intervention types | behavioral, other, device |
| Target enrollment | 264 |
| Site countries | South Korea |
| Posted | 2026-11-03 |
| Planned start | 2026-10-29 |
| Event | Newly registered study |
| Event date | 2026-11-03 |

## Why this score
- Posted in the last two weeks.
- 264 participants planned.
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07911839). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.